Differential Role of Leptin and Adiponectin in Cardiovascular System

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Ghantous, C M ^a   Azrak, Z ^a   Hanache, S ^a   Abou Kheir, W ^a   Zeidan, A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; JANUS KINASE; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHO FACTOR; STAT PROTEIN;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPERTENSION; IN VITRO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; OBESITY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK FACTOR;

EID: 84929990793     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/534320     Document Type: Review

References (155)

1. R. Weiss, S. Dufour, A. Groszmann et al., "Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation," Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 2014-2018, 2003.
2. J. H. Lee, D. R. Reed, and R. A. Price, "Leptin resistance is associated with extreme obesity and aggregates in families," International Journal of Obesity, vol. 25, no. 10, pp. 1471-1473, 2001.
3. J. M. Friedman and J. L. Halaas, "Leptin and the regulation of body weight in mammals," Nature, vol. 395, no. 6704, pp. 763-770, 1998.
4. L. Huang and C. Li, "Leptin: a multifunctional hormone," Cell Research, vol. 10, no. 2, pp. 81-92, 2000.
5. A. Zeidan and M. Karmazyn, "Leptin and vascular smooth muscle," Current Vascular Pharmacology, vol. 4, no. 4, pp. 383-393, 2006.
6. L. A. Campfield, F. J. Smith, and P. Burn, "The OB protein (leptin) pathway - a link between adipose tissue mass and central neural networks," Hormone and Metabolic Research, vol. 28, no. 12, pp. 619-632, 1996.
7. H. Matsui, M. Motooka, H. Koike et al., "Ischemia/reperfusion in rat heart induces leptin and leptin receptor gene expression," Life Sciences, vol. 80, no. 7, pp. 672-680, 2007.
8. A. Zeidan, D. M. Purdham, V. Rajapurohitam, S. Javadov, S. Chakrabarti, and M. Karmazyn, "Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy," Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 3, pp. 1075-1084, 2005.
9. S.-C. Chen, J. P. Kochan, L. A. Campfield, P. Burn, and R. J. Smeyne, "Splice variants of the OB receptor gene are differentially expressed in brain and peripheral tissues of mice," Journal of Receptor and Signal Transduction Research, vol. 19, no. 1-4, pp. 245-266, 1999.
10. L. Marroquí, A. Gonzalez, P. Neco et al., "Role of leptin in the pancreatic β-cell: effects and signaling pathways," Journal of Molecular Endocrinology, vol. 49, no. 1, pp. R9-R17, 2012.
11. M. E. Hall, G. Smith, J. E. Hall, and D. E. Stec, "Cardiomyocyte-specific deletion of leptin receptors causes lethal heart failure in Cre-recombinase-mediated cardiotoxicity," The American Journal of Physiology - Regulatory Integrative and Comparative Physiology, vol. 303, no. 12, pp. R1241-R1250, 2012.
12. C. P. Briscoe, S. Hanif, J. R. S. Arch, and M. Tadayyon, "Leptin receptor long-form signalling in a human liver cell line," Cytokine, vol. 14, no. 4, pp. 225-229, 2001.
13. G. Wolf, S. Chen, D. C. Han, and F. N. Ziyadeh, "Leptin and renal disease," American Journal of Kidney Diseases, vol. 39, no. 1, pp. 1-11, 2002.
14. V. Rajapurohitam, X. T. Gan, L. A. Kirshenbaum, and M. Karmazyn, "The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes," Circulation Research, vol. 93, no. 4, pp. 277-279, 2003.
15. J. Mütze, J. Roth, R. Gerstberger, K. Matsumura, and T. Hübschle, "Immunohistochemical evidence of functional leptin receptor expression in neuronal and endothelial cells of the rat brain," Neuroscience Letters, vol. 394, no. 2, pp. 105-110, 2006.
16. A. Markowska, A. S. Belloni, M. Ructnski et al., "Leptin and leptin receptor expression in the myometrium and uterine myomas: is leptin involved in tumor development?" International Journal of Oncology, vol. 27, no. 6, pp. 1505-1509, 2005.
17. C. Bjørbæk, S. Uotani, B. da Silva, and J. S. Flier, "Divergent signaling capacities of the long and short isoforms of the leptin receptor," The Journal of Biological Chemistry, vol. 272, no. 51, pp. 32686-32695, 1997.
18. J. D. Knudson, Ü. D. Dincer, C. Zhang et al., "Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction," The American Journal of Physiology: Heart and Circulatory Physiology, vol. 289, no. 1, pp. H48-H56, 2005.
19. S. Margetic, C. Gazzola, G. G. Pegg, and R. A. Hill, "Leptin: a review of its peripheral actions and interactions," International Journal of Obesity, vol. 26, no. 11, pp. 1407-1433, 2002.
20. K. Rahmouni and W. G. Haynes, "Leptin and the cardiovascular system," Recent Progress in Hormone Research, vol. 59, pp. 225-244, 2004.
21. P. Fernández-Riejos, S. Najib, J. Santos-Alvarez et al., "Role of leptin in the activation of immune cells," Mediators of Inflammation, vol. 2010, Article ID 568343, 8 pages, 2010.
22. M. K. Sinha, I. Opentanova, J. P. Ohannesian et al., "Evidence of free and bound leptin in human circulation: studies in lean and obese subjects and during short-term fasting," Journal of Clinical Investigation, vol. 98, no. 6, pp. 1277-1282, 1996.
23. S. K. Fried, M. R. Ricci, C. D. Russell, and B. Laferrere, "Regulation of leptin production in humans," Journal of Nutrition, vol. 130, pp. 3127S-3131S, 2000.
24. R. A. Coleman and T. S. Herrmann, "Nutritional regulation of leptin in humans," Diabetologia, vol. 42, no. 6, pp. 639-646, 1999.
25. T. G. Ramsay and M. P. Richards, "Leptin and leptin receptor expression in skeletal muscle and adipose tissue in response to in vivo porcine somatotropin treatment," Journal of Animal Science, vol. 83, no. 11, pp. 2501-2508, 2005.
26. G.-H. Lee, R. Proenca, J. M. Montez et al., "Abnormal splicing of the leptin receptor in diabetic mice," Nature, vol. 379, no. 6566, pp. 632-635, 1996.
27. H. Ge, L. Huang, T. Pourbahrami, and C. Li, "Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo," Journal of Biological Chemistry, vol. 277, no. 48, pp. 45898-45903, 2002.
28. R. S. Ahima and S. Y. Osei, "Leptin signaling," Physiology and Behavior, vol. 81, no. 2, pp. 223-241, 2004.
29. C. Vaisse, J. L. Halaas, C. M. Horvath, J. E. Dernell Jr., M. Stoffel, and J. M. Friedman, "Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice," Nature Genetics, vol. 14, no. 1, pp. 95-97, 1996.
30. D. W. White, K. K. Kuropatwinski, R. Devos, H. Baumann, and L. A. Tartaglia, "Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization," The Journal of Biological Chemistry, vol. 272, no. 7, pp. 4065-4071, 1997.
31. K. Nakashima, M. Narazaki, and T. Taga, "Leptin receptor (OB-R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130," FEBS Letters, vol. 403, no. 1, pp. 79-82, 1997.
32. C. Kloek, A. K. Haq, S. L. Dunn, H. J. Lavery, A. S. Banks, and M. G. Myers Jr., "Regulation of Jak kinases by intracellular leptin receptor sequences," The Journal of Biological Chemistry, vol. 277, no. 44, pp. 41547-41555, 2002.
33. A. S. Banks, S. M. Davis, S. H. Bates, and M. G. Myers Jr., "Activation of downstream signals by the long form of the leptin receptor," Journal of Biological Chemistry, vol. 275, no. 19, pp. 14563-14572, 2000.
34. S. Eyckerman, D. Broekaert, A. Verhee, J. Vandekerckhove, and J. Tavernier, "Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor," FEBS Letters, vol. 486, no. 1, pp. 33-37, 2000.
35. P. Hekerman, J. Zeidler, S. Bamberg-Lemper et al., "Pleiotropy of leptin receptor signalling is defined by distinct roles of the intracellular tyrosines," FEBS Journal, vol. 272, no. 1, pp. 109-119, 2005.
36. S. H. Bates and M. G. Myers, "The role of leptin → STAT3 signaling in neuroendocrine function: an integrative perspective," Journal of Molecular Medicine, vol. 82, no. 1, pp. 12-20, 2004.
37. H. Münzberg, M. Björnholm, S. H. Bates, and M. G. Myers Jr., "Leptin receptor action and mechanisms of leptin resistance," Cellular and Molecular Life Sciences, vol. 62, no. 6, pp. 642-652, 2005.
38. C. Bjørbæk, R. M. Buchholz, S. M. Davis et al., "Divergent roles of SHP-2 in ERK activation by leptin receptors," The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4747-4755, 2001.
39. S. L. Dunn, M. Björnholm, S. H. Bates, Z. Chen, M. Seifert, and M. G. Myers Jr., "Feedback inhibition of leptin receptor/Jak2 signaling via Tyr 1138 of the leptin receptor and suppressor of cytokine signaling 3," Molecular Endocrinology, vol. 19, no. 4, pp. 925-938, 2005.
40. S. H. Bates and M. G. Myers Jr., "The role of leptin receptor signaling in feeding and neuroendocrine function," Trends in Endocrinology and Metabolism, vol. 14, no. 10, pp. 447-452, 2003.
41. K. D. Niswender, B. Gallis, J. E. Blevins, M. A. Corson, M. W. Schwartz, and D. G. Baskin, "Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin," Journal of Histochemistry and Cytochemistry, vol. 51, no. 3, pp. 275-283, 2003.
42. C. C. T. Smith, M. M. Mocanu, S. M. Davidson, A. M. Wynne, J. C. Simpkin, and D. M. Yellon, "Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects," British Journal of Pharmacology, vol. 149, no. 1, pp. 5-13, 2006.
43. P. Tajmir, R. B. Ceddia, R.-K. Li, I. R. Coe, and G. Sweeney, "Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase- and phosphatidylinositol 3-kinase-dependent signaling pathways," Endocrinology, vol. 145, no. 4, pp. 1550-1555, 2004.
44. R. S. Ahima and J. S. Flier, "Leptin," Annual Review of Physiology, vol. 62, pp. 413-437, 2000.
45. M. R. Stofega, J. Herrington, N. Billestrup, and C. Carter-Su, "Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B," Molecular Endocrinology, vol. 14, no. 9, pp. 1338-1350, 2000.
46. O. Gualillo, S. Eiras, D. W. White, C. Diéguez, and F. F. Casanueva, "Leptin promotes the tyrosine phosphorylation of SHC proteins and SHC association with GRB2," Molecular and Cellular Endocrinology, vol. 190, no. 1-2, pp. 83-89, 2002.
47. S. V. Y. Raju, M. Zheng, K. H. Schuleri et al., "Activation of the cardiac ciliary neurotrophic factor receptor reverses left ventricular hypertrophy in leptin-deficient and leptin-resistant obesity," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 11, pp. 4222-4227, 2006.
48. Y. Wang, S. Huang, V. P. Sah et al., "Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family," The Journal of Biological Chemistry, vol. 273, no. 4, pp. 2161-2168, 1998.
49. H.-J. Shin, J. Oh, S. M. Kang et al., "Leptin induces hypertrophy via p38 mitogen-activated protein kinase in rat vascular smooth muscle cells," Biochemical and Biophysical Research Communications, vol. 329, no. 1, pp. 18-24, 2005.
50. K. Ohashi, K. Nagata, M. Maekawa, T. Ishizaki, S. Narumiya, and K. Mizuno, "Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop," The Journal of Biological Chemistry, vol. 275, no. 5, pp. 3577-3582, 2000.
51. A. Zeidan, B. Paylor, K. J. Steinhoff et al., "Actin cytoskeleton dynamics promotes leptin-induced vascular smooth muscle hypertrophy via RhoA/ROCK- and phosphatidylinositol 3-kinase/protein kinase B-dependent pathways," Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 3, pp. 1110-1116, 2007.
52. T. J. Nelson, R. Balza Jr., Q. Xiao, and R. P. Misra, "SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy," Journal of Molecular and Cellular Cardiology, vol. 39, no. 3, pp. 479-489, 2005.
53. A. Zeidan, S. Javadov, and M. Karmazyn, "Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes," Cardiovascular Research, vol. 72, no. 1, pp. 101-111, 2006.
54. M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan, "Leptin as a cardiac hypertrophic factor: a potential target for therapeutics," Trends in Cardiovascular Medicine, vol. 17, no. 6, pp. 206-211, 2007.
55. W. Lieb, L. M. Sullivan, T. B. Harris et al., "Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals," Diabetes Care, vol. 32, no. 4, pp. 612-616, 2009.
56. B. H. Lorell and B. A. Carabello, "Left ventricular hypertrophy: pathogenesis, detection, and prognosis," Circulation, vol. 102, no. 4, pp. 470-479, 2000.
57. D. Levy, J. M. Murabito, K. M. Anderson, J. C. Christiansen, and W. P. Castelli, "Echocardiographic left ventricular hypertrophy: clinical characteristics. The Framingham Heart Study," Clinical and Experimental Hypertension A: Theory and Practice, vol. 14, no. 1-2, pp. 85-97, 1992.
58. J. C. Tardiff, "Cardiac hypertrophy: stressing out the heart," Journal of Clinical Investigation, vol. 116, no. 6, pp. 1467-1470, 2006.
59. A. W. Haider, M. G. Larson, E. J. Benjamin, and D. Levy, "Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death," Journal of the American College of Cardiology, vol. 32, no. 5, pp. 1454-1459, 1998.
60. R. Yang and L. A. Barouch, "Leptin signaling and obesity: cardiovascular consequences," Circulation Research, vol. 101, no. 6, pp. 545-559, 2007.
61. L. A. Barouch, D. E. Berkowitz, R. W. Harrison, C. P. O'Donnell, and J. M. Hare, "Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice," Circulation, vol. 108, no. 6, pp. 754-759, 2003.
62. W. T. Gibson, I. S. Farooqi, M. Moreau et al., "Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy," Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 4821-4826, 2004.
63. G. Paz-Filho, C. Mastronardi, T. Delibasi, M.-L. Wong, and J. Licinio, "Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy," Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 54, no. 8, pp. 690-697, 2010.
64. P. E. Bravo, S. Morse, D. M. Borne, E. A. Aguilar, and E. Reisin, "Leptin and hypertension in obesity," Vascular Health and Risk Management, vol. 2, no. 2, pp. 163-169, 2006.
65. M. Pladevall, K. Williams, H. Guyer et al., "The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study," Journal of Hypertension, vol. 21, no. 8, pp. 1467-1473, 2003.
66. M. A. Allison, D. A. Bluemke, R. McClelland et al., "Relation of leptin to left ventricular hypertrophy (from the multi-ethnic study of atherosclerosis)," The American Journal of Cardiology, vol. 112, no. 5, pp. 726-730, 2013.
67. M. Mapfei, J. Halaas, E. Ravussin et al., "Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects," Nature Medicine, vol. 1, no. 11, pp. 1155-1161, 1995.
68. T. Shioi, P. M. Kang, P. S. Douglas et al., "The conserved phosphoinositide 3-kinase pathway determines heart size in mice," The EMBO Journal, vol. 19, no. 11, pp. 2537-2548, 2000.
69. Y.-K. Kim, S.-J. Kim, A. Yatani et al., "Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt," The Journal of Biological Chemistry, vol. 278, no. 48, pp. 47622-47628, 2003.
70. J. R. McMullen, M. C. Sherwood, O. Tarnavski et al., "Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload," Circulation, vol. 109, no. 24, pp. 3050-3055, 2004.
71. L. Perego, P. Pizzocri, D. Corradi et al., "Circulating leptin correlates with left ventricular mass in morbid (Grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy," The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 7, pp. 4087-4093, 2005.
72. G. Paolisso, M. R. Tagliamonte, M. Galderisi et al., "Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men," Hypertension, vol. 34, no. 5, pp. 1047-1052, 1999.
73. R. M. Casto, J. M. Van Ness, and J. M. Overton, "Effects of central leptin administration on blood pressure in normotensive rats," Neuroscience Letters, vol. 246, no. 1, pp. 29-32, 1998.
74. E. W. Shek, M. W. Brands, and J. E. Hall, "Chronic leptin infusion increases arterial pressure," Hypertension, vol. 31, no. 1, pp. 409-414, 1998.
75. M. Shimizu, N. Sugihara, Y. Kita et al., "Long term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy," British Heart Journal, vol. 67, no. 2, pp. 155-160, 1992.
76. G. Paolisso, M. Galderisi, M. R. Tagliamonte et al., "Myocardial wall thickness and left ventricular geometry in hypertensives: relationship with insulin," American Journal of Hypertension, vol. 10, no. 11, pp. 1250-1256, 1997.
77. K. K. Hintz, N. S. Aberle II, and J. Ren, "Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes," International Journal of Obesity, vol. 27, no. 10, pp. 1196-1203, 2003.
78. G. M. Reaven, H. Lithell, and L. Landsberg, "Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system," The New England Journal of Medicine, vol. 334, no. 6, pp. 374-381, 1996.
79. M. L. G. Correia, D. A. Morgan, W. I. Sivitz, A. L. Mark, and W. G. Haynes, "Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure," Hypertension, vol. 37, no. 3, pp. 936-942, 2001.
80. M. Carlyle, O. B. Jones, J. J. Kuo, and J. E. Hall, "Chronic cardiovascular and renal actions of leptin: role of adrenergic activity," Hypertension, vol. 39, no. 2, pp. 496-501, 2002.
81. A. Bouloumié, T. Marumo, M. Lafontan, and R. Busse, "Leptin induces oxidative stress in human endothelial cells," The FASEB Journal, vol. 13, no. 10, pp. 1231-1238, 1999.
82. S.-I. Yamagishi, D. Edelstein, X.-L. Du, Y. Kaneda, M. Guzmán, and M. Brownlee, "Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A," Journal of Biological Chemistry, vol. 276, no. 27, pp. 25096-25100, 2001.
83. S. Loffreda, S. Q. Yang, H. Z. Lin et al., "Leptin regulates proinflammatory immune responses," The FASEB Journal, vol. 12, no. 1, pp. 57-65, 1998.
84. P. Quehenberger, M. Exner, R. Sunder-Plassmann et al., "Leptin induces endothelin-1 in endothelial cells in vitro," Circulation Research, vol. 90, no. 6, pp. 711-718, 2002.
85. E. Grossman, "Does increased oxidative stress cause hypertension?" Diabetes Care, vol. 31, supplement 2, pp. S185-S189, 2008.
86. F. Maingrette and G. Renier, "Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C," Diabetes, vol. 52, no. 8, pp. 2121-2128, 2003.
87. T. M. Paravicini and R. M. Touyz, "Redox signaling in hypertension," Cardiovascular Research, vol. 71, no. 2, pp. 247-258, 2006.
88. T. Suganami, M. Mukoyama, K. Mori et al., "Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy," The FASEB Journal, vol. 19, no. 1, pp. 127-129, 2005.
89. M. Morales-Ruiz, D. Fulton, G. Sowa et al., "Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt," Circulation Research, vol. 86, no. 8, pp. 892-896, 2000.
90. A. Oda, T. Taniguchi, and M. Yokoyama, "Leptin stimulates rat aortic smooth muscle cell proliferation and migration," Kobe Journal of Medical Sciences, vol. 47, no. 3, pp. 141-150, 2001.
91. S. Goetze, A. Bungenstock, C. Czupalla et al., "Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands," Hypertension, vol. 40, no. 5, pp. 748-754, 2002.
92. I. Szanto and C. R. Kahn, "Selective interaction between leptin and insulin signaling pathways in a hepatic cell line," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 5, pp. 2355-2360, 2000.
93. C. Vecchione, A. Maffei, S. Colella et al., "Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway," Diabetes, vol. 51, no. 1, pp. 168-173, 2002.
94. H.-Y. Park, H. M. Kwon, H. J. Lim et al., "Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro," Experimental and Molecular Medicine, vol. 33, no. 2, pp. 95-102, 2001.
95. K. Kume, K. Satomura, S. Nishisho et al., "Potential role of leptin in endochondral ossification," Journal of Histochemistry and Cytochemistry, vol. 50, no. 2, pp. 159-169, 2002.
96. W. G. Stetler-Stevenson, "Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention," The Journal of Clinical Investigation, vol. 103, no. 9, pp. 1237-1241, 1999.
97. N. Maulik and D. K. Das, "Redox signaling in vascular angiogenesis," Free Radical Biology and Medicine, vol. 33, no. 8, pp. 1047-1060, 2002.
98. E. Mata-Greenwood, A. Grobe, S. Kumar, Y. Noskina, and S. M. Black, "Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-beta1 and reactive oxygen species: a requirement for NAD(P)H oxidase," The American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 289, no. 2, pp. L288-L289, 2005.
99. M. R. Sierra-Honigmann, A. K. Nath, C. Murakami et al., "Biological action of leptin as an angiogenic factor," Science, vol. 281, no. 5383, pp. 1683-1686, 1998.
100. K. Schäfer, M. Halle, C. Goeschen et al., "Leptin promotes vascular remodeling and neointimal growth in mice," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 1, pp. 112-117, 2004.
101. K. Stephenson, J. Tunstead, A. Tsai, R. Gordon, S. Henderson, and H. M. Dansky, "Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 11, pp. 2027-2033, 2003.
102. F. Huang, X. Xiong, H. Wang, S. You, and H. Zeng, "Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-κB," Acta Biochimica et Biophysica Sinica, vol. 42, no. 5, pp. 325-331, 2010.
103. K. Kaibuchi, S. Kuroda, and M. Amano, "Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells," Annual Review of Biochemistry, vol. 68, pp. 459-486, 1999.
104. M. Nakata, T. Yada, N. Soejima, and I. Maruyama, "Leptin promotes aggregation of human platelets via the long form of its receptor," Diabetes, vol. 48, no. 2, pp. 426-429, 1999.
105. J. Santos-Alvarez, R. Goberna, and V. Sánchez-Margalet, "Human leptin stimulates proliferation and activation of human circulating monocytes," Cellular Immunology, vol. 194, no. 1, pp. 6-11, 1999.
106. R. Faggioni, K. R. Feingold, and C. Grunfeld, "Leptin regulation of the immune response and the immunodeficiency of malnutrition,"The FASEB Journal, vol. 15, no. 14, pp. 2565-2571, 2001.
107. G. M. Lord, G. Matarese, J. K. Howard, R. J. Baker, S. R. Bloom, and R. I. Lechler, "Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression," Nature, vol. 394, no. 6696, pp. 897-901, 1998.
108. R. M. Touyz and E. L. Schiffrin, "Reactive oxygen species in vascular biology: implications in hypertension," Histochemistry and Cell Biology, vol. 122, no. 4, pp. 339-352, 2004.
109. D. Harrison, K. K. Griendling, U. Landmesser, B. Hornig, and H. Drexler, "Role of oxidative stress in atherosclerosis," American Journal of Cardiology, vol. 91, no. 3, pp. 7A-11A, 2003.
110. P. Libby, P. M. Ridker, and A. Maseri, "Inflammation and atherosclerosis," Circulation, vol. 105, no. 9, pp. 1135-1143, 2002.
111. -/- mice," Atherosclerosis, vol. 225, no. 2, pp. 341-347, 2012.
112. Y. Arita, S. Kihara, N. Ouchi et al., "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999," Biochemical and Biophysical Research Communications, vol. 425, no. 3, pp. 560-564, 2012.
113. C. Bambace, M. Telesca, E. Zoico et al., "Adiponectin gene expression and adipocyte diameter: a comparison between epicardial and subcutaneous adipose tissue inmen," Cardiovascular Pathology, vol. 20, no. 5, pp. e153-e156, 2011.
114. B. J. Goldstein, R. G. Scalia, and X. L. Ma, "Protective vascular and myocardial effects of adiponectin," Nature Clinical Practice Cardiovascular Medicine, vol. 6, no. 1, pp. 27-35, 2008.
115. A. H. Berg, T. P. Combs, X. Du, M. Brownlee, and P. E. Scherer, "The adipocyte-secreted protein Acrp30 enhances hepatic insulin action," Nature Medicine, vol. 7, no. 8, pp. 947-953, 2001.
116. N. Ouchi, S. Kihara, Y. Arita et al., "Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway," Circulation, vol. 102, no. 11, pp. 1296-1301, 2000.
117. W. Zhu, K. K. Y. Cheng, P. M. Vanhoutte, K. S. L. Lam, and A. Xu, "Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention," Clinical Science, vol. 114, no. 5-6, pp. 361-374, 2008.
118. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, "Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome," Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784-1792, 2006.
119. S. Suzuki, E. M. Wilson-Kubalek, D. Wert, T.-S. Tsao, and D. H. Lee, "The oligomeric structure of high molecular weight adiponectin," The FEBS Letters, vol. 581, no. 5, pp. 809-814, 2007.
120. X. Hui, K. S. Lam, P. M. Vanhoutte, and A. Xu, "Adiponectin and cardiovascular health: an update," British Journal of Pharmacology, vol. 165, no. 3, pp. 574-590, 2012.
121. K. Saito, T. Tobe, S. Minoshima et al., "Organization of the gene for gelatin-binding protein (GBP28)," Gene, vol. 229, no. 1-2, pp. 67-73, 1999.
122. M. Stumvoll, O. Tschritter, A. Fritsche et al., "Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes," Diabetes, vol. 51, no. 1, pp. 37-41, 2002.
123. H. Ebinuma, T. Miida, T. Yamauchi et al., "Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid," Clinical Chemistry, vol. 53, no. 8, pp. 1541-1544, 2007.
124. T.-S. Tsao, E. Tomas, H. E. Murrey et al., "Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways," The Journal of Biological Chemistry, vol. 278, no. 50, pp. 50810-50817, 2003.
125. U. B. Pajvani, X. Du, T. P. Combs et al., "Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin: implications for metabolic regulation and bioactivity," The Journal of Biological Chemistry, vol. 278, no. 11, pp. 9073-9085, 2003.
126. T. Yamauchi, J. Kamon, Y. Ito et al., "Cloning of adiponectin receptors that mediate antidiabetic metabolic effects," Nature, vol. 423, no. 6941, pp. 762-769, 2003.
127. E. Tomas, T.-S. Tsao, A. K. Saha et al., "Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16309-16313, 2002.
128. T. Yamauchi, J. Kamon, Y. Minokoshi et al., "Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase," Nature Medicine, vol. 8, no. 11, pp. 1288-1295, 2002.
129. T. Yamauchi, Y. Nio, T. Maki et al., "Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions," Nature Medicine, vol. 13, no. 3, pp. 332-339, 2007.
130. M. Bjursell, A. Ahnmark, M. Bohlooly-Y et al., "Opposing effects of adiponectin receptors 1 and 2 on energy metabolism," Diabetes, vol. 56, no. 3, pp. 583-593, 2007.
131. Y. Liu, M. D. Michael, S. Kash et al., "Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes," Endocrinology, vol. 148, no. 2, pp. 683-692, 2007.
132. C. Hug, J. Wang, N. S. Ahmad, J. S. Bogan, T.-S. Tsao, and H. F. Lodish, "T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 28, pp. 10308-10313, 2004.
133. T. Takeuchi, Y. Adachi, Y. Ohtsuki, and M. Furihata, "Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease," Medical Molecular Morphology, vol. 40, no. 3, pp. 115-120, 2007.
134. M. S. Denzel, M.-C. Scimia, P. M. Zumstein, K. Walsh, P. Ruiz-Lozano, and B. Ranscht, "T-cadherin is critical for adiponectin-mediated cardioprotection in mice," The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4342-4352, 2010.
135. R. Shibata, Y. Izumiya, K. Sato et al., "Adiponectin protects against the development of systolic dysfunction following myocardial infarction," Journal of Molecular and Cellular Cardiology, vol. 42, no. 6, pp. 1065-1074, 2007.
136. R. Shibata, K. Sato, D. R. Pimentel et al., "Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms," Nature Medicine, vol. 11, no. 10, pp. 1096-1103, 2005.
137. M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan, "Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart," Cardiovascular Research, vol. 79, no. 2, pp. 279-286, 2008.
138. S. Plant, B. Shand, P. Elder, and R. Scott, "Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins," Diabetes and Vascular Disease Research, vol. 5, no. 2, pp. 102-108, 2008.
139. C. Caselli, A. D'Amico, M. Cabiati, T. Prescimone, S. Del Ry, and D. Giannessi, "Back to the heart: the protective role of adiponectin," Pharmacological Research, vol. 82, pp. 9-20, 2014.
140. E. C. M. Mariman and P. Wang, "Adipocyte extracellular matrix composition, dynamics and role in obesity," Cellular and Molecular Life Sciences, vol. 67, no. 8, pp. 1277-1292, 2010.
141. Z. Chen, I.-C. Peng, W. Sun et al., "AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633," Circulation Research, vol. 104, no. 4, pp. 496-505, 2009.
142. P. Wang, T.-Y. Xu, Y.-F. Guan, D.-F. Su, G.-R. Fan, and C.-Y. Miao, "Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mono-nucleotide," Cardiovascular Research, vol. 81, no. 2, pp. 370-380, 2009.
143. M.-A. Ewart, C. F. Kohlhaas, and I. P. Salt, "Inhibition of tumor necrosis factor α-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 12, pp. 2255-2257, 2008.
144. H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, "Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells," Biochemical and Biophysical Research Communications, vol. 408, no. 2, pp. 339-343, 2011.
145. Y. Arita, S. Kihara, N. Ouchi et al., "Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell," Circulation, vol. 105, no. 24, pp. 2893-2898, 2002.
146. M. Matsuda, I. Shimomura, M. Sata et al., "Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis," The Journal of Biological Chemistry, vol. 277, no. 40, pp. 37487-37491, 2002.
147. C. Kobashi, M. Urakaze, M. Kishida et al., "Adiponectin inhibits endothelial synthesis of interleukin-8," Circulation Research, vol. 97, no. 12, pp. 1245-1252, 2005.
148. P. Zhang, Y. Wang, Y. Fan, Z. Tang, and N. Wang, "Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 1, pp. 67-74, 2009.
149. I. Afanas'ev, "ROS and RNS signaling in heart disorders: could antioxidant treatment be successful?" Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 293769, 13 pages, 2011.
150. R. Meng, Z. Pei, A. Zhang et al., "AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway," Archives of Biochemistry and Biophysics, vol. 511, no. 1-2, pp. 1-7, 2011.
151. P. S. Jhund and J. J. V. McMurray, "Heart failure after acute myocardial infarction a lost battle in the war on heart failure?" Circulation, vol. 118, no. 20, pp. 2019-2021, 2008.
152. C. J. Weinheimer, L. Lai, D. P. Kelly, and A. Kovacs, "Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure," Clinical and Experimental Pharmacology and Physiology, vol. 42, no. 1, pp. 33-40, 2015.
153. M. Y. Baden, Y. Yamada, Y. Takahi et al., "Association of adiponectin with blood pressure in healthy people," Clinical Endocrinology, vol. 78, no. 2, pp. 226-231, 2013.
154. A. M. Thøgersen, S. Söderberg, J.-H. Jansson et al., "Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction," European Journal of Cardiovascular Prevention and Rehabilitation, vol. 11, no. 1, pp. 33-40, 2004.
155. S. M. Wallerstedt, A.-L. Eriksson, A. Niklason, C. Ohlsson, and T. Hedner, "Serum leptin and myocardial infarction in hypertension," Blood Pressure, vol. 13, no. 4, pp. 243-246, 2004.